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with implanted pacemakers and deﬁbrillators in the mag-
netic resonance imaging (MRI) environment, evaluation of lead
electrode heating is the most complex because of the many
inﬂuencing variables: patient size, anatomy, body composition,
patient position in the bore, scan sequence (radiofrequency power
level), lead routing, and lead design. Although clinical studies are
an important step in demonstrating efﬁcacy, demonstrating safety
through clinical trials alone is not practical because of this
complexity.
OBJECTIVE The purpose of this study was to develop a compre-
hensive modeling framework to predict the probability of pacing
capture threshold (PCT) change due to lead electrode heating in the
MRI environment and thus provide a robust safety evaluation.
METHODS The lead heating risk was assessed via PCT change
because this parameter is the most clinically relevant measure of
lead heating. The probability for PCT change was obtained by
combining the prediction for power at the electrode–tissue inter-
face obtained via simulations with a prediction for PCT change as a
function of radiofrequency power obtained via an in vivo
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probability of a 0.5-V PCT change due to an MRI scan for the
Medtronic CapSureFix MRI SureScan model 5086 MRI leads is o1/
70,000 for chest scans ando1/10,000,000 for either head scans or
lower torso scans.
CONCLUSION The framework efﬁciently models millions of combi-
nations, delivering a robust evaluation of the lead electrode
heating hazard. This modeling approach provides a comprehensive
safety evaluation that is impossible to achieve using phantom
testing, animal studies, or clinical trials alone.
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Regarded by many as the gold standard for soft tissue
imaging, magnetic resonance imaging (MRI) has become the
imaging modality of choice for neurologic, soft tissue,
tumors, and musculoskeletal disorders.1 The prevalence of
common comorbidities increases rapidly for individuals
older than 65 years, resulting in an increasing likelihood of
beneﬁting from MRI.2–4 For example, pacemaker patients,
who on average are 75 years of age,5,6 have a 70% chance of
developing an indication for an MRI scan over the expected
life of the implanted device.7 MRI scans have beenconsidered contraindicated for pacemaker patients since the
development of MRI more than 30 years ago. MR Condi-
tional pacing and deﬁbrillator systems represent a techno-
logical breakthrough in the medical device industry,
addressing a compelling market need with signiﬁcant patient
beneﬁt.MRI system: Source of hazards
MRI scanners deliver pulsed radiofrequency (RF) and
switched gradient magnetic ﬁelds in the presence of a
powerful static magnetic ﬁeld to create an image of the
body. Together, the three powerful ﬁelds (static, RF, and
switched gradient) create a hostile environment for an
implantable pacing or deﬁbrillation system.8 However, with
proper design and evaluation methods, it is possible to
mitigate the hazards and produce a system that will allow
patients to be safely scanned.http://dx.doi.org/10.1016/j.hrthm.2013.10.009
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deﬁbrillators undergoing MRI scans ﬁt into several cate-
gories: (1) arrhythmias initiated by MRI-induced cardiac
stimulation, (2) RF-induced tissue heating near the lead
electrodes causing tissue damage, (3) temporary or perma-
nent device malfunction that results in inappropriate therapy,
and (4) device and/or lead dislodgement, caused by inter-
action between the static and fast switching gradient mag-
netic ﬁeld and ferrous materials.Figure 2 Strategy for evaluating the probability for pacing capture
threshold (PCT) change as a result of magnetic resonance imaging (MRI)
scans. Lead electrode heating is quantiﬁed via a computer model with a
number of inputs: human body models (which account for variation in
patient size, anatomy, and body composition), patient position in the bore,
radiofrequency (RF) coil models, lead routings, and lead-speciﬁc electrical
models (which account for variation in lead design). The physiologic effect
of the heating is measured in an in vivo canine study. The ﬁnal output of the
model is the probability of PCT change due to an MRI scan.Rationale for computer modeling
The lead electrode heating complexity is due to a combina-
tion of multiple clinical variables, including patient size,
anatomy, body composition, patient position in the bore,
scan sequence (RF power level), lead routing, and lead
design. This leads to a signiﬁcant variation in lead electrode
heating. Figure 1 shows lead electrode heating variation due
to patient size (three different human body models), patient
position in the bore (shown along the x-axis), and lead
routing in the body (four different lead routings are shown
using different color lines). Figure 1 illustrates the extreme
variation in lead electrode heating due to these variables: (1)
there is at least a 10 difference between the highest- and
lowest-heating lead routings within a speciﬁc human body
model; (2) the highest- and lowest-heating lead routings are
different for different human body models (e.g., compare the
lead routing marked with a black line); and (3) the peak
heating is different for different size human body models.
Computer-aided modeling is a practical and efﬁcient
method for exploring millions of variable combinations in a
holistic manner. Computer modeling also allows for analysis
of parameter extremes, outside the bounds of normal clinical
practice, which allows further assessment of safety margin and
the sensitivity of inﬂuencing variables. The accuracy of
modeling results is dependent on the ability to simulate and
predict real use scenarios. The objective of this study was toFigure 1 Lead electrode heating variation due to patient size (three
different human body models), patient position in the bore (shown along the
x-axis), and lead routing in the body (four different lead routings shown
using different color lines). For each patient, the left point corresponds to
lower torso scans and the right point corresponds to head scans.develop a robust modeling framework to predict risk of lead
electrode heating in the MRI environment and thus provide a
robust safety evaluation for new and existing products.
MRI lead electrode model overview
The modeling framework consists of two major parts: (1) the
RF power at the electrode–tissue interface is simulated using
models of human bodies, RF coils, leads, and lead routings;
and (2) the effect of RF power on pacing capture threshold
(PCT) is evaluated in vivo via a canine study. PCT is the
minimum voltage required to pace, or capture, the heart. The
results of these two steps are combined to develop a
statistical prediction of PCT change during an MRI scan.
A block diagram of the strategy is shown in Figure 2. Note
that this approach does not rely on in vivo temperature rise
measurements because the relationship between the change
in PCT and RF power is directly obtained.
PCT was chosen as the basis of the lead electrode heating
evaluation strategy because the change in PCT is directly
caused by tissue heating near the lead electrode. In addition,
it is the most sensitive parameter for monitoring changes in
the electrode–tissue interface and is the parameter of most
signiﬁcance with respect to pacing therapy delivery.
Models of human bodies, RF coils, leads, and lead
routings are simulated in order to calculate the coupled RF
power. In addition, an in vivo canine study is performed to
measure PCT change as a function of RF power delivered
directly to the cardiac lead. These two components are
combined in order to calculate the probability of MRI-
induced PCT change.
Methods
As discussed in the Introduction, the modeling framework
consists of two parts: (1) the simulations that predict lead
Figure 3 Coronal and sagittal views of 1000 three-dimensional anatomic
lead routes (blue lines) in one human body model.
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study that measures PCT change as a function of RF power.
These two parts are discussed in more detail below.
Part 1: Lead Electrode Heating Simulations
RF coil models
Medtronic Cardiac Rhythm Disease Management has
assembled a library of seven RF coil models from four
major manufacturers. These models were simulated using the
SEMCAD X (version 14.8.1) electromagnetic simulation
software (Speag, Zurich, Switzerland). The SEMCAD X
software uses the ﬁnite difference time domain (FDTD)
method, which is a widely accepted numerical analysis
technique for electrodynamics.9
Human body models
Because the amount of lead electrode heating depends on
patient size and anatomy, a library of human body models
was developed. These bodies are anatomically correct and
span the 2nd to 97th percentile of the adult human population
in height and weight (height range 154–187 cm, weight
range 42–114 kg).10 All tissues in each human body model
were assigned with appropriate electromagnetic properties.
In the simulations, each of the human body models is placed
inside the RF coil in various locations in order to mimic a
patient undergoing an MRI scan. The result is a three-
dimensional electromagnetic ﬁeld induced in the
human body.
Cardiac lead modeling
An electromagnetic model of the cardiac lead at the 1.5-T
magnetic resonance frequency (64 MHz) was developed in
order to predict the power dissipated in tissue near the lead
electrode due to the electric ﬁeld distribution along the lead
body. The cardiac lead modeling must accurately describe
two phenomena: (1) the RF energy coupling to the lead body
and (2) the RF energy propagation through the lead body to
the lead electrode–tissue interface. The lead model is
empirically derived by measuring the voltage drop at the
lead electrode due to a unit voltage applied along the lead
body.11 Because of differences in lead body and electrode
constructions between different lead types (e.g., pacing
leads, deﬁbrillation leads, active ﬁxation, passive ﬁxation),
a different electromagnetic model must be derived for every
lead type. Lead models for several different Medtronic
pacing and deﬁbrillation leads were experimentally eval-
uated using this methodology (see further discussion in
“Comparative lead electrode heating assessment” in the
Results section and “Interpretation of the modeling” in the
Discussion).
Lead routings
The RF energy that couples to the lead is a function of the
electric ﬁeld along the lead. The electric ﬁeld in the human
body is highly heterogeneous due to anatomic complexity.
One thousand clinically relevant and anatomically correctlead routings were developed, created from pacemaker
patient chest X-ray images (Figure 3). Using this method-
ology, it is possible to simulate approximately 2.4 million
unique cases (¼ 19 body models * 9 positions in RF coil * 7
RF coils * 2 electric ﬁeld polarizations * 1000 lead routes).Model validation
In order to ensure accuracy of the model, model validation
was performed in vitro in a body phantom ﬁlled with a
homogeneous saline solution. The variables included as part
of in vitromodel validation are shown in Table 1. Simulation
results were compared to empirical measurements for well-
deﬁned cases. In order to ensure that the model retained
validity for a large number of scenarios, values for a number
of parameters were varied among extreme cases.Part 2: PCT as a function of RF power
The physiologic effect of lead electrode heating was eval-
uated via an in vivo canine study, which measured the change
in PCT as a function of RF power. Four modiﬁed 5086 MRI
leads were implanted in eight canines (two leads in the right
atrium, two leads in the right ventricle), for a total of 32
leads. The modiﬁed leads consist of a micro-coaxial cable
connected to the 5086 MRI lead distal end (tip and ring
electrodes) and enable accurate quantiﬁcation of the amount
of RF power that reaches the electrode–tissue interface. After
implantation, the leads were allowed to mature for 6 weeks,
followed by application of RF power to the leads for 15
minutes. PCT was measured before RF application and 5
minutes after RF application. The change in PCT was
deﬁned as PCT 5 minutes after RF application minus PCT
prior to RF application.Results
Model validation results
Figure 4 shows the results of model validation for the
different lengths of the CapSureFix MRI SureScan model
5086 MRI lead. Excellent agreement was found between the
Table 1 Variables used for in vitro model validation of the 5086 MRI lead
Variable Description
Z-landmark The Z-landmark deﬁnes the position of the phantom in the longitudinal direction within the bore of the MRI coil.
Solution
conductivity
Because the solution is electrically homogenous (unlike a human body), the solution conductivity was varied to mimic
various tissue types.
Solution depth Four solution depths were chosen in order to approximate how different size patients load the MRI coil.
Lead length Three standard lengths (45, 52, 58 cm) were used.
Lead routing A number of lead routes were chosen in order to achieve sufﬁcient diversity of the electric ﬁeld distributions along the
lead.
Routing level Varying lead routing heights correspond to different distances of the leads from the surface of the solution, which ensured
a diversity of electric ﬁelds.
MRI ¼ magnetic resonance imaging.
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racy for the model.
Comparative lead electrode heating assessment
In order to further demonstrate the power of the modeling
framework presented here, Figure 5 shows the normalized
simulated lead electrode dissipated power for several differ-
ent Medtronic cardiac pacing and deﬁbrillation leads. The
dissipated power is normalized to the 5086 MRI 52-cm
power. The shaded bars (leads “A”–“E”) correspond to leads
that have secured MR Conditional labeling in at least one
geography; leads “F”–“I” have not yet been evaluated for
MR Conditional labeling.
5086 MRI lead
The modeling framework combines simulated RF power
dissipated at the lead electrode with the RF-induced PCT
change empirically measured in the animal studies. The
results of the 5086 MRI animal study are shown in Figure 6.
The solid curve shows the mean change in PCT as a function
of dissipated power at the lead electrode. The dashed curves
show the 95% conﬁdence bounds. These data show a gradual
onset of PCT change as dissipated power increases. Also, the
change in PCT is linear with dissipated power. Note that forFigure 4 Results of in vitro model validation for the 5086 MRI lead. The
three sets of points are for three different lengths of the 5086 MRI lead.
Excellent agreement is seen between the simulated and measured powers,
indicating very good accuracy in the electromagnetic model of the lead.the 5086 MRI lead, clinically relevant dissipated power
levels are below approximately 110 mW, where PCT change
is extremely unlikely. Clinically relevant dissipated power
levels differ by lead.
The ﬁnal result of the analysis generates a probability that
a patient with an implanted cardiac system undergoing an
MRI scan will experience a change in PCT. Table 2 lists PCT
change probabilities from simulations for the 5086 MRI lead
for different scan types (head only, chest only, lower torso/
legs only). The probability of PCT change is highest for the
chest-only scan, which s to be expected because in this
orientation the implanted system is in the middle of the bore,
where the electric ﬁeld, and therefore heating, is highest. The
model is powerful and ﬂexible because it allows one to alter
different inputs, such as lead route or patient position in the
bore, to see the effect on the probability of PCT change.
Discussion
Evaluating the impact of MR exposure to patients with
cardiovascular implantable electronic devices is largely
dependent on the potential for heating induced at the tip of
the leads and the changes in capture threshold induced by
that heating. Because thousands of permutations of variables
and conditions must be accounted for in this evaluation, only
a modeling framework can practically provide a full assess-
ment. We required both a simulation model that predicts lead
electrode heating (RF power) and an in vivo canine study that
measured PCT change as a function of RF power. Together
this provides a robust assessment.
Interpretation of the modeling
When there is a translation of the induced RF power into
capture threshold changes, it places the model in speciﬁc
context of a particular lead. However, it is inappropriate to
draw conclusions about the relative safety of the leads in
Figure 5 without the in vivo data because there are no
established requirements for RF-induced lead heating.
Industry and regulators are working with traditional stand-
ards organizations (International Organization for Stand-
ardization [ISO] and Association for the Advancement of
Medical Instrumentation [AAMI]) to establish test methods
and requirements for each MRI-induced patient hazard.
When this work is complete, it is possible that leads F–I
will also secure MR Conditional labeling. In the mean time,
Figure 5 Normalized simulated lead electrode dissipated power for several different Medtronic pacing and deﬁbrillation leads. All dissipated powers are
normalized to the dissipated power of lead “A” (5086 MRI 52 cm). Lead models are labeled “A” through “I” on the horizontal axis. Leads “A” through “E” are
coaxial pacing leads, whereas leads “F” through “I” are multilumen deﬁbrillation leads. From the ﬁgure, one can see there is a 2.5 difference in heating among
pacing leads alone and a greater difference (8) compared to the deﬁbrillation leads. Bars with diagonal lines (“A”–“E”) represent lead models that have secured
MR Conditional labeling in at least one geography. Leads “F”–“I” have not yet been evaluated for MR Conditional labeling. It is impossible to evaluate safety
from these data alone because an animal study would need to be conducted for each lead model to evaluate the physiologic effect of the dissipated power.
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comfort level with the evidence presented.
The power of the modeling approach is the ability to
quickly analyze several million combinations of patient
attributes, implanted system attributes, and scan sequence
permutations to derive the comparative analysis shown in
Figure 5. This modeling approach has been adopted by the
ISO and AAMI efforts and likely will become the expected
method for evaluating MRI-induced lead heating.12Clinical implications
PCT is the most basic clinical measurement of lead function
made by heart rhythm professionals. Variation in PCT occurs
within a single encounter, often 0.5 V. Normal variation in
PCT, up to 1.0 V, is often observed, without concern for lead
system integrity.13 Small MRI-induced elevations of temper-
ature produce small elevations in PCT. These perturbations
of capture efﬁciency are for relatively brief durations becauseFigure 6 Change in pacing capture threshold (PCT) as a function of
radiofrequency (RF) power dissipated at the lead tip–tissue interface
collected in chronic canine study. ΔPCT was calculated by subtracting the
pre-RF PCT measurement from the PCT measurement after each exposure.
Solid line shows the mean change in PCT. Dashed lines indicate the 95%
conﬁdence bounds. Note that clinically relevant power levels for the model
5086 MRI lead are below approximately 110 mW, where no PCT change is
expected.the temperature changes are small. The ability to predict the
magnitude of the heating also strongly correlates to patient
safety. The data presented here for the 5086 MRI lead show
that the probability of an acute 1.0-V change in PCT as a
result of an MRI scan is extremely low and likely would not
be observed in a clinical setting. The EnRhythmMRI clinical
study randomized patients to receive an MRI scan (MRI
group) or to not receive an MRI (control group).14 The
number of patients experiencing a 0.5-V increase in PCT
following MRI (or no MRI) was slightly higher in the control
group than in the MRI group; only one subject had a 1.0-V
increase in ventricular PCT, and this patient was in the
control group. This study concluded that, regarding the
signiﬁcant changes in PCT (atrial and ventricular), the
MRI group was statistically equivalent (deﬁned as within
10%) to the control group. It can be observed from these
study data that changes of this magnitude may be attributed
to normal variation in cardiac electrophysiology. Similarly,
the modeling results presented in Table 2 predicted that a
change in PCT due to MRI for the 5086 MRI lead is remote.
In the canine study, acute PCT measurements were made
5 minutes after RF application to accelerate the execution of
the study. However, the majority of the healing response of
cardiac tissue to thermal injury is complete approximately 2
to 4 weeks after RF application. Data gathered in parallel
canine studies indicate that acute PCT changes measured 5
minutes postinjection are larger than chronic PCT changes
(measured at the 2-week end-point).
This human body modeling framework was used to
predict the probability of change in PCT for a population
of pacemaker or deﬁbrillator patients with a particularTable 2 Probability for MRI-induced pacing capture threshold
change (0.5 and 1.0 V) for 5086 MRI leads for different scan types
0.5 V 1.0 V
Chest scan only o1/70,000 o1/1,400,000
Head scan only o1/10,000,000 o1/10,000,000
Lower torso only o1/10,000,000 o1/10,000,000
MRI ¼ magnetic resonance imaging.
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The electromagnetic model depends on the frequency of the
RF ﬁeld, which is directly proportional to the static magnet
strength. Therefore, it is important to note that the results for
probability of PCT change presented here are not directly
applicable to other static magnet strengths (e.g., 0.1 or 3 T).
However, similar methodology can be used to analyze lead
electrode heating at other static magnet strengths.
Regulatory implications
Medtronic Cardiac Rhythm Disease Management has used
this modeling data to support regulatory submissions for
approval of MR Conditional products. In particular, the
modeling data have been the primary vehicle to demonstrate
system safety. In addition, two conﬁrmatory clinical trials of
SureScan systems, the EnRhythm MRI study14 and the
Advisa MRI study,15 were supplemental to this modeling
data for Food and Drug Administration submissions. Both
trials conﬁrmed the SureScan system was safe in the MRI
environment when labeling was followed, adding conﬁdence
to the modeling approach. Outside the United States, the
human body modeling has also been used extensively to gain
CE mark and regulatory approval in a number of other
geographies (e.g., Canada, Europe, Japan, and Korea).
Evaluating products for safety
Although several cardiac devices are currently market
released as MR Conditional, the development of new
products as well as the safety evaluation of currently released
products for the MRI environment is becoming a focus of
many device manufacturers. The development of a lead
electrode heating model provides a comprehensive safety
evaluation of thousands of scenarios not reachable in a
clinical trial and allows evaluation of safety margin by
simulation of key variable values beyond the range of
standard clinical practice.
Publications reporting case studies of successful MRI
scans in patients with implanted cardiac devices are common
in journals today.16–26 Many describe a small number of
patients who have undergone an MRI scan without compli-
cation. Because there are thousands of permutations, obser-
vational data that only test a few conditions cannot support a
claim of safety. The complete assessment of a lead in the
MRI environment through modeling is the future of safety
evaluation. With the ability to provide data for thousands of
combinations of variables, lead heating modeling demon-
strates safety outside a clinical study and provides a pathway
to provide safety conﬁrmation to physicians and products to
patients more quickly.
Conclusion
The analysis of MRI risk for patients with implanted pace-
makers or deﬁbrillators is extremely complex because of the
many variables that inﬂuence lead heating: patient size,
anatomy, body composition, patient position in the bore,
scan sequence (RF power level), lead routing, and leaddesign. Although clinical studies play an important con-
ﬁrmatory role, demonstration of safety through clinical trials
is not practical. Likewise, phantom and animal testing play
an important role in deriving the modeling results but at this
time are not sufﬁcient by themselves to assess safety.
The modeling framework presented herein provides for
the evaluation of millions of combinations of variables in
order to predict the probability of PCT change as a result of
an MRI scan. The results presented here are speciﬁc to the
5086 MRI lead and 1.5-T MRI scanners. Although these
results are not directly applicable to leads or scanners other
than 1.5 T, a similar methodology can be used to analyze
other leads (e.g., pacing, deﬁbrillation, and cardiac resynch-
ronization) and static magnetic strengths. The robustness of
the modeling framework provides assurance of safety to
physicians, patients, and regulators.Acknowledgments
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